8-K: Tevogen Bio Implements 1-for-50 Reverse Stock Split

Tevogen Bio Holdings Inc. announced a 1-for-50 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, effective March 6, 2026.

Summary

• Tevogen Bio Holdings Inc. filed a Certificate of Amendment to its Certificate of Incorporation to effect a 1-for-50 reverse stock split of its common stock.
• The reverse stock split will be effective as of March 6, 2026, at 12:01 a.m. Eastern Time.
• The primary purpose is to regain compliance with the Nasdaq Global Market's $1.00 minimum bid price requirement.
• Stockholders approved the reverse stock split on February 19, 2026, granting the Board discretion on the final ratio.
• As of March 3, 2026, there were 202,416,556 shares of common stock issued and outstanding, which will be reduced by a 1-for-50 ratio.
• No fractional shares will be issued; instead, stockholders will receive cash based on the closing trading price on the day prior to the effective date.
• The number of authorized shares (800,000,000 common, 20,000,000 preferred) will not change.
• Outstanding convertible preferred stock and warrants will be adjusted proportionally.
• The CUSIP number for the common stock will change to 88165K200, while the trading symbol (TVGN) will remain unchanged.
• The reverse stock split will not affect stockholders' percentage ownership interest, except for fractional share treatment, nor will it affect business operations or total stockholders' equity.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a necessary but concerning corporate action. While it addresses a critical listing requirement, the underlying need for a reverse split often signals significant challenges in market valuation and investor sentiment, despite the company's ongoing R&D efforts.

Positives

• The reverse stock split aims to ensure continued listing on the Nasdaq Global Market, which is crucial for liquidity and investor confidence.
• The company's underlying business operations and total stockholders' equity are stated to be unaffected by the split.
• The company continues to leverage artificial intelligence and precision T cell therapy platforms for advanced therapies.
• Tevogen Bio's lead initiative has completed a proof-of-concept clinical trial demonstrating the potential of its allogeneic T cells.
• The company is exploring future strategic initiatives including domestic generics, biosimilars, medical devices, and innovative insurance solutions.

Negatives

• The necessity of a reverse stock split indicates that the company's stock price has fallen below Nasdaq's minimum bid price requirement, suggesting poor market performance.
• Stockholders will own fewer shares of common stock, which can sometimes be perceived negatively by the market, despite the proportional value remaining the same.
• Fractional shares will be settled in cash, potentially forcing some stockholders to liquidate a small portion of their holdings.

Risks

• Changes in the markets in which Tevogen competes, including competitive landscape, technology evolution, or regulatory changes.
• Changes in domestic and global general economic conditions.
• Risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations.
• Risk that Tevogen may not be able to develop and maintain effective internal controls.
• Failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities.
• Risk that Tevogen may fail to keep pace with rapid technological developments or make substantial investments in unsuccessful new products and services.
• Need to raise additional capital to fully realize business plans.
• Risks related to the ability to develop, license, or acquire new therapeutics.
• Risk of regulatory lawsuits or proceedings relating to Tevogen's business.
• Uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials.
• Risks related to regulatory review, approval, and commercial development.
• Risks associated with intellectual property protection.
• Tevogen's limited operating history.

Future Outlook

Tevogen Bio anticipates that the reverse stock split will enable it to regain compliance with Nasdaq's minimum bid price requirement, ensuring continued listing. The company continues to focus on developing advanced, life-saving therapies across multiple therapeutic areas using AI and precision T cell therapy platforms, with a pipeline spanning virology, oncology, and neurology. Future strategic initiatives may include domestic generics, biosimilars, medical devices, and innovative insurance solutions.

Management Comments

• The Board of Directors has approved a reverse stock split of its common stock at a ratio of 50 for 1.
• The reverse stock split is being conducted to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market.
• The reverse stock split will be applicable to all holders of our common stock uniformly and will not affect any stockholders percentage of ownership interest in the Company, except for any changes resulting from the treatment of fractional shares.
• The reverse stock split will not affect the Company's underlying business operations or total stockholders equity.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common corporate action in the biotechnology and pharmaceutical sectors, often employed by companies whose stock prices have fallen below exchange minimums due to factors such as prolonged R&D cycles, clinical trial setbacks, or market skepticism. While necessary for maintaining listing, such actions can sometimes signal underlying challenges in achieving commercial milestones or sustained investor confidence, contrasting with more mature industry players that typically maintain higher stock valuations.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies, particularly in the biotech sector, to maintain listing compliance on major exchanges like Nasdaq. For example, similar actions have been taken by companies such as Sorrento Therapeutics (SRNEQ) and Aeterna Zentaris (AEZS) in the past when facing delisting threats due to low share prices.
• The 1-for-50 ratio is a significant consolidation, indicating a substantial need to boost the per-share price. This is a higher ratio than some, but not unprecedented. For instance, some companies have implemented 1-for-10 or 1-for-20 splits, while others have gone as high as 1-for-100 or more, depending on the severity of the stock price decline.
• The stated goal of maintaining Nasdaq listing is a standard objective for such actions, as delisting can severely impact liquidity, investor access, and institutional interest, which is critical for growth-stage biotech firms like Tevogen.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but the proportional ownership interest remains the same (except for fractional shares which are cashed out). The goal is to maintain Nasdaq listing, which benefits shareholders by preserving liquidity and market access.
• Warrant Holders/Convertible Security Holders: Their securities will be adjusted proportionally, meaning the number of shares they can convert/exercise into will decrease, and the conversion/exercise price will increase, maintaining the same aggregate value.

Next Steps

• Common stock will begin trading on Nasdaq on a split-adjusted basis at the open of business on March 6, 2026.
• Continental Stock Transfer and Trust Company (and brokers/banks for beneficial owners) will electronically adjust stockholder holdings.
• The company will continue its development of advanced, life-saving therapies across multiple therapeutic areas.
• Tevogen is exploring future strategic initiatives including domestic generics, biosimilars, medical devices, and innovative insurance solutions.

Key Dates

Recommendation

While the reverse stock split is a necessary step to maintain Nasdaq listing and avoid delisting, it signals underlying challenges with the company's market valuation. The action itself does not fundamentally change the company's business operations or total equity. Investors should hold to observe if the company can leverage its AI and T-cell therapy platforms to achieve significant clinical or commercial milestones that would justify a higher valuation, rather than selling purely on the reverse split news. However, the need for such a drastic measure suggests caution, and a 'buy' recommendation would be premature without clearer positive catalysts.

Keywords

Tevogen Bio Holdings Inc., TVGN, Reverse Stock Split, Nasdaq Compliance, Biotechnology, T-cell Therapy, Artificial Intelligence, Healthcare, SEC Filing, Corporate Action